구조모아 (StructureMoa)항암 chemical structure spider web
방문분석
큐레이션 브리핑
경쟁 포지션: Primary challenger to Eylea/Eylea HD on injection interval.
기전. Neutralizes VEGF-A to reduce neovascularization and permeability while blocking Ang-2 to restore Tie2 signaling and vascular stability, reducing inflammation-driven leakage.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
Ang-2 / VEGF-A
Wet AMD, diabetic macular edema, macular edema following retinal vein occlusion
US, EU, JP
Approved
vabysmo · faricimab · Vabysmo · RG7716 · faricimab-svoa
2026-09-10
Data Confidence · High
Development Signal · Established
Bispecific antibody (CrossMAb)
One anti-Ang-2 arm and one anti-VEGF-A arm with an Fc engineered to reduce systemic exposure and effector function
Dual pathway blockade targets vascular instability, not just leakage, which is what supports extended intervals.
구조화 데이터
Dual pathway blockade targets vascular instability, not just leakage, which is what supports extended intervals.
Persistent fluid despite dual blockade; interval shortening in a subset of eyes.
Bispecific antibody (CrossMAb)
Ang-2 / VEGF-A · OCT central subfield thickness, BCVA, presence of intraretinal fluid.
Endophthalmitis, intraocular inflammation, and IOP monitoring
Primary challenger to Eylea/Eylea HD on injection interval.
Neovascular AMD, DME, and RVO-associated macular edema
1L anti-VEGF alternative
Intravitreal injection
Up to q16w after loading in nAMD and DME
Endophthalmitis, intraocular inflammation, and IOP monitoring
Primary challenger to Eylea/Eylea HD on injection interval.
Neutralizes VEGF-A to reduce neovascularization and permeability while blocking Ang-2 to restore Tie2 signaling and vascular stability, reducing inflammation-driven leakage.
OCT central subfield thickness, BCVA, presence of intraretinal fluid.
Persistent fluid despite dual blockade; interval shortening in a subset of eyes.
구조화 데이터
Human, primate
Ocular ~7.5 days; minimal systemic exposure by design
CST reduction, fluid-free intervals, BCVA change
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA approval (wet AMD and DME)
APPROVAL · 2022년 1월
Macular edema following RVO indication
APPROVAL · 2023년 10월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
분석
큐레이션 브리핑
경쟁 포지션: Primary challenger to Eylea/Eylea HD on injection interval.
기전. Neutralizes VEGF-A to reduce neovascularization and permeability while blocking Ang-2 to restore Tie2 signaling and vascular stability, reducing inflammation-driven leakage.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
Ang-2 / VEGF-A
Wet AMD, diabetic macular edema, macular edema following retinal vein occlusion
US, EU, JP
Approved
vabysmo · faricimab · Vabysmo · RG7716 · faricimab-svoa
2026-09-10
Data Confidence · High
Development Signal · Established
Bispecific antibody (CrossMAb)
One anti-Ang-2 arm and one anti-VEGF-A arm with an Fc engineered to reduce systemic exposure and effector function
Dual pathway blockade targets vascular instability, not just leakage, which is what supports extended intervals.
구조화 데이터
Dual pathway blockade targets vascular instability, not just leakage, which is what supports extended intervals.
Persistent fluid despite dual blockade; interval shortening in a subset of eyes.
Bispecific antibody (CrossMAb)
Ang-2 / VEGF-A · OCT central subfield thickness, BCVA, presence of intraretinal fluid.
Endophthalmitis, intraocular inflammation, and IOP monitoring
Primary challenger to Eylea/Eylea HD on injection interval.
Neovascular AMD, DME, and RVO-associated macular edema
1L anti-VEGF alternative
Intravitreal injection
Up to q16w after loading in nAMD and DME
Endophthalmitis, intraocular inflammation, and IOP monitoring
Primary challenger to Eylea/Eylea HD on injection interval.
Neutralizes VEGF-A to reduce neovascularization and permeability while blocking Ang-2 to restore Tie2 signaling and vascular stability, reducing inflammation-driven leakage.
OCT central subfield thickness, BCVA, presence of intraretinal fluid.
Persistent fluid despite dual blockade; interval shortening in a subset of eyes.
구조화 데이터
Human, primate
Ocular ~7.5 days; minimal systemic exposure by design
CST reduction, fluid-free intervals, BCVA change
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA approval (wet AMD and DME)
APPROVAL · 2022년 1월
Macular edema following RVO indication
APPROVAL · 2023년 10월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.